Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. - Wikidata - wikimedia - TriplyDB

Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy.

Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy.

http://www.wikidata.org/entity/Q34524972

about

Nortriptyline for neuropathic pain in adults Recommendations for the pharmacological management of neuropathic pain: an overview and literature update A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy.North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial Therapeutic strategies for cancer treatment related peripheral neuropathies.EFNS guidelines on pharmacological treatment of neuropathic pain.A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy Platinum-induced neurotoxicity and preventive strategies: past, present, and future The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.Influence of dosing times on cisplatin-induced peripheral neuropathy in rats.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.The pharmacotherapy of chronic pain: a review.Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises Cancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners.Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis.Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature.Chemotherapy-induced peripheral neuropathy: prevention and treatment.Coanalgesics for chronic pain therapy: a narrative review.Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.Management options for established chemotherapy-induced peripheral neuropathy.Cancer treatment-related neuropathic pain syndromes--epidemiology and treatment: an update.Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives.Pregabalin in Chemotherapy Induced Neuropathic Pain.Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.Pain in chemotherapy-induced peripheral neurotoxicity.Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin.

P2860

Q24186696-938AB54A-D34F-4708-AC87-4676C5B99934 Q24616897-AE11CDF1-E4BC-433C-BD48-A623990EFB9E Q33693343-A5036208-20EF-4585-8D4F-E730C3DBB36C Q33711666-1F8F5CFA-15B1-4C04-B500-AD2362C31967 Q33717608-1703AB17-8C26-49BD-B831-7BDFD66647B3 Q33744706-4C1E8567-31DF-4738-A11F-40A68A8DD0BA Q33889319-78A80B67-457A-4D12-8270-4353DCD1427F Q33984071-48BDAAA4-4144-414A-984C-170DEDA482FF Q34336573-326EC73C-D914-4A7C-8873-7937E4D3409F Q34433406-5ECBB89D-A2A9-4C36-A1D1-04CE7790E412 Q34573607-3C447D54-5F67-40EC-A1C9-645F409DA80D Q34619839-775481E0-8F91-4563-A99E-6845BFE63723 Q35248852-CB04932A-D36B-4B23-AD27-23A8056BFBBC Q35248891-CC7558D5-7919-47F3-9274-F6DBFF9E46AB Q35345734-4DEC37DB-F089-48AF-9529-09446EC986DA Q35898610-FDDB15B2-AF6A-404A-B5E9-B31A07E29EAE Q36057728-AA5346F2-C2B7-4025-B8FA-79ECE7D9D8CE Q36146524-5F77F438-3B98-406C-8ACB-890CFDD8437E Q36226275-DAC6DAB4-3700-4E91-8394-B39E18EAC835 Q36411163-971484D0-517D-4E1B-8A73-427E56F60DEB Q37018248-664463A4-E71A-45F4-BC2B-B72160D823FE Q37046151-5705EC05-9CC0-4A7D-98E4-769C3B6A7C1E Q37364316-36469EC4-A0F6-4743-8FEC-BB66A56D393E Q37631063-BAFD508B-DBC5-4410-AA82-07AE3786F542 Q37764968-25FBC9BA-5457-42EE-9B96-13E28B1D355E Q37844531-2244E50B-0076-4024-B8FA-72CE4A122EF1 Q37907386-97522697-97EE-4B67-B92A-16D5331B7C06 Q37911252-01032377-E2EA-4262-90D7-8001E29ACDA3 Q37959164-520F6B5C-4393-4BC6-B75A-A9C0B9D3D3C7 Q38191773-AEBA1978-4022-4C24-8638-01547080AB55 Q38216217-8308E90B-AF60-4D68-95FA-9E9C4490A5B5 Q38252761-2075667C-3512-4E34-98B0-B3714ABABBA8 Q38254351-B2CAB6B8-0FE8-4819-B2B0-00DBD980323F Q38264622-4A88BA13-F9B0-42F6-8D6C-C266C223F642 Q38522262-7B7703F1-EA3D-40DB-AA41-9952BAF7C0A1 Q38644156-43ECEE1B-54F7-427B-905C-09AA2D339A1B Q39138091-8C713F51-1641-4818-A55E-CC9FC86B4D54 Q39363713-ED075264-5F24-4186-8EFD-B845B32A727C Q41242322-5A62E926-2373-4DED-B3C0-A3A847E984C1 Q41852990-4676D1EA-D5EE-4492-A646-C4A15C2E9336

P2860

Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy.

http://www.wikidata.org/entity/Q34524972

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@ast

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@en

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@nl

type

label

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@ast

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@en

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@nl

prefLabel

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@ast

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@en

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@nl

P1433

Q34524972-FF6E8BE3-067F-47B3-AFC2-7F563D21E953

P1476

Q34524972-7F113292-692A-4485-89E8-CE3C233B4E2E

P2093

Q34524972-3BB55E2B-E283-4602-8740-959830C598D2

Q34524972-3CC11AEF-4D3E-49F8-B1D7-E6607C5529B3

Q34524972-40806661-8D25-4AB8-8A02-1217C73F12EF

Q34524972-436D5795-8330-4F86-B15F-5E578A67B383

Q34524972-A02D16CF-0C63-4DDD-8AB1-53E1182FFD19

Q34524972-A63B4AAC-35BF-45E2-B226-3D13ADD0E5EF

Q34524972-D3B43317-D42C-41B4-9CB6-C648665FC99F

Q34524972-D6F01E67-A73C-4420-A8E8-9CAD91A66FF8

Q34524972-FA1A0A47-F390-4A2C-BFCB-880CB591A7EB

Q34524972-FC151BBA-79C5-45D5-AD79-852875F0ECB8

P304

Q34524972-4DE6AF07-156C-4A16-90AB-884EF3EFAE2E

P31

Q34524972-7295FF72-D04B-40C6-B59F-190B91ACAA8B

P356

Q34524972-9F1CDEC0-202B-4ADA-ACA1-577AE3709A8E

P407

Q34524972-F23A8962-905F-4A3B-8590-16F56C84E04D

P433

Q34524972-A38F352A-3C31-4076-A34D-453B78EC0405

P478

Q34524972-15AE7CF3-15C4-4363-A0B1-DB65CC2797E0

P577

Q34524972-4032CA6C-3434-41B4-8849-8D4C195F1C40

P698

Q34524972-2D9AFA7E-18BE-4895-9152-D6C6B19149A5

P356

S0304-3959(02)00047-7

P1433

P1476

Phase III evaluation of nortri ...... induced peripheral neuropathy.

@en

P2093

Charles L Loprinzi

http://www.w3.org/2001/XMLSchema#string

Gamini S Soori

http://www.w3.org/2001/XMLSchema#string

Jeff A Sloan

http://www.w3.org/2001/XMLSchema#string

Joanne A Johnson

http://www.w3.org/2001/XMLSchema#string

John C Michalak

http://www.w3.org/2001/XMLSchema#string

Julie E Hammack

http://www.w3.org/2001/XMLSchema#string

Kendrith M Rowland

http://www.w3.org/2001/XMLSchema#string

Maria Tria Tirona

http://www.w3.org/2001/XMLSchema#string

Paul J Novotny

http://www.w3.org/2001/XMLSchema#string

Philip J Stella

http://www.w3.org/2001/XMLSchema#string

P304

195-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0304-3959(02)00047-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12098632

http://www.w3.org/2001/XMLSchema#string